Loading...
XLONFAB
Market cap8mUSD
Dec 24, Last price  
7.00GBP
1D
0.00%
1Q
57.30%
IPO
-95.45%
Name

Fusion Antibodies PLC

Chart & Performance

D1W1MN
XLON:FAB chart
P/E
—
P/S
591.26
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
20.25%
Rev. gr., 5y
-12.24%
Revenues
1m
-60.84%
404,997723,046909,2941,481,2651,913,9562,690,7442,181,8383,895,0004,165,0004,799,0002,901,0001,136,000
Net income
-2m
L-14.25%
-468,737-113,538-85,1121,154,092119,954-699,941-1,264,382-697,000-2,899,000-1,200,000-2,596,000-2,226,000
CFO
-2m
L+0.80%
00-182,050346,570-37,37477,192-1,098,350-166,000-1,151,000-333,000-1,755,000-1,769,000
Earnings
Sep 03, 2025

Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
URL
https://fusionantibodies.com/
IPO date
Dec 18, 2017
Employees
55
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
1,136
-60.84%
2,901
-39.55%
4,799
15.22%
Cost of revenue
3,428
5,734
6,131
Unusual Expense (Income)
NOPBT
(2,292)
(2,833)
(1,332)
NOPBT Margin
Operating Taxes
(63)
(263)
(133)
Tax Rate
NOPAT
(2,229)
(2,570)
(1,199)
Net income
(2,226)
-14.25%
(2,596)
116.33%
(1,200)
-58.61%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,808
116
BB yield
-134.78%
-0.75%
Debt
Debt current
20
35
66
Long-term debt
66
80
6
Deferred revenue
Other long-term liabilities
20
20
20
Net debt
(1,113)
(80)
(1,977)
Cash flow
Cash from operating activities
(1,769)
(1,755)
(333)
CAPEX
(2)
(114)
(258)
Cash from investing activities
1,000
(114)
(258)
Cash from financing activities
2,770
7
(46)
FCF
(1,313)
(1,590)
(539)
Balance
Cash
1,199
195
2,049
Long term investments
Excess cash
1,142
50
1,809
Stockholders' equity
(5,950)
(6,524)
(3,963)
Invested Capital
7,806
7,606
7,668
ROIC
ROCE
EV
Common stock shares outstanding
55,556
26,015
25,946
Price
0.04
-90.26%
0.39
-35.83%
0.60
-61.78%
Market cap
2,083
-79.20%
10,016
-35.66%
15,567
-61.05%
EV
970
9,936
13,590
EBITDA
(2,072)
(2,461)
(581)
EV/EBITDA
Interest
5
4
9
Interest/NOPBT